US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer
The Assessment Group, January 2011, Pages: 59
Treatment choices of 174 high-prescribing oncologists in response to clinical patient scenarios. Provides rich insights into specific treatment decisions, factors influencing their decisions, barriers to care, and confidence in managing these patients.
Series of clinical patient cases presented to the oncologists followed by clinical questions for open-ended responses on how they would treat and manage the patient and why. Data has been synthesized to show the highest reported responses, other responses, and direct quotes from the oncologists.
- Understand actual clinical decisions that are being made in real patient situations.
- Understand the most current practice patterns among high-prescribing oncologists.
- Understand what kinds of practice variations exist and why.
This report answers these questions:
- What treatment choices are being made first for advanced disease?
- What is the next choice upon further disease progression?
- How confident is the oncologist in this decision?
- What are the barriers to optimal patient care?
- Where does your product fit in their decisions and why?
- Where are new products going to fit?
- How do oncologists view currently available treatments?
Patient Case Highlights:
- Triple negative metastatic breast cancer
- Triple positive metastatic breast cancer
- ER/PR positive HER2neu negative metastatic breast cancer
- Metastatic breast cancer with multiple comorbidities
Use this report to:
- Understand the most up-to-date prescribing trends and the factors that influence treatment decisions
- Recognize why certain clinical decisions are being made
- Learn where there are needs of your target audience
- Discover opportunities to improve the position of your product
- Design messages to improve brand performance
- Segment target audiences by practice patterns
- Focus where there are gaps and needs for information
Executive Summary
Chapter 1: Introduction
Table 1. Treatment Options in Metastatic Breast Cancer
Chapter 2: Respondent Demographics
Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State’s Breast Cancer Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
Chapter 3: Treatment of a Patient with Triple Negative Metastatic Breast Cancer Figure 3.1 Choice of chemotherapy regimen, triple negative metastatic breast cancer
Figure 3.2 Single chemotherapy choices, triple negative metastatic breast cancer
Figure 3.3 Combination chemotherapy choices, triple negative metastatic breast cancer
Figure 3.4 Factors influencing treatment of triple negative metastatic breast cancer
Figure 3.5 Confidence managing patient with triple negative metastatic breast cancer
Figure 3.6 Other agents appropriate to include in treatment of triple negative metastatic breast cancer
Figure 3.7 Treatment of progressive triple negative metastatic breast cancer
Figure 3.8 Single chemotherapy agent, progressive triple negative metastatic breast cancer
Figure 3.9 Combination chemotherapy, progressive triple negative metastatic breast cancer
Figure 3.10 Barriers to optimal treatment of progressive triple negative metastatic breast cancer
Figure 3.11 Changing therapy to manage neuropathy
Figure 3.12 Recommended treatment of progressive triple negative metastatic breast cancer with BRCA-1 mutation
Figure 3.13 Single agent chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation
Figure 3.14 Combination chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation
Chapter 4: Treatment of Patient with Triple Positive Metastatic Breast Cancer
Figure 4.1 Next step for patient with triple positive metastatic breast cancer
Figure 4.2 Treatment of progressive disease, triple positive metastatic breast cancer
Figure 4.3 Single chemotherapy choices for progressive triple positive metastatic breast cancer
Figure 4.4 Combination chemotherapy, progressive triple positive metastatic breast cancer
Figure 4.5 Factors influencing treatment of progressive triple positive metastatic breast cancer
Figure 4.6 Treatment regimen for continued progression of triple positive metastatic breast cancer
Figure 4.7 Decisions regarding the use of lapatinib in progressive triple positive metastatic breast cancer
Figure 4.8 Management of progressive disease, triple positive metastatic breast cancer
Chapter 5: Patient with ER/PR Positive HER2Neu Negative Metastatic Breast Cancer
Figure 5.1 Confidence managing patient with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.2 Other than analgesics, treatment of patient’s hip pain with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.3 Treatment with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.4 Factors influencing treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.5 Next systemic treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer
Chapter 6: Patient with Metastatic Breast Cancer with Multiple Comorbidities
Figure 6.1 Confidence managing patient with metastatic breast cancer with multiple comorbidities
Figure 6.2 Barriers to managing patient, metastatic breast cancer with multiple comorbidities
Figure 6.3 Treatment in addition to the aromatase inhibitor for patient’s metastatic breast cancer with multiple comorbidities
Figure 6.4 Next treatment regimen for progressive metastatic breast cancer with multiple comorbidities
Figure 6.5 Factors influencing treatment for progressive metastatic breast cancer with multiple comorbidities
Chapter 7: Summary
Appendix A: Survey Instrument
- Amgen
- AstraZeneca
- Bristol-Myers Squibb
- Celgene Corporation Centocor
- Eisai Pharmaceuticals
- Eli Lilly & Company
- Genentech Inc.
- laxoSmithKline
- Ortho Biotech
- Novartis
- Pfizer, Inc.
- Sanofi-aventis
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
